Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objectives of this study was to evaluate the safety and efficacy of avacincaptad pegol intravitreal administration in participants with geographic atrophy secondary to age-related macular degeneration (AMD)
Participants were randomized in a 1:1 ratio to the following monthly treatment groups:
At Month 12, the participants in the avacincaptad pegol 2mg treatment group were re-randomized to receive the study drug either on a monthly basis or on an every other month basis
The participants initially randomized to sham treatment continued with monthly sham administration through Month 23
All participants had a final follow up visit at Month 24
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Avacincaptad Pegol | Experimental | Participants received avacincaptad pegol (ACP) 2 milligram (mg)/eye via intravitreal (IVT) injections monthly through Month 11 (Year 1). At month 12, participants were re-randomized to receive ACP 2 mg/eye via IVT injections monthly from month12 through month 23 (Year 2). |
|
| Sham | Sham Comparator | Participants received sham injections; through Month 11 (Year 1). At month 12, participants continued to receive monthly sham administration from month 12 through month 23 (Year 2). |
|
| Avacincaptad pegol and Sham | Experimental | Participants who received ACP 2mg monthly through Month 11 (Year 1) were re-randomized at month 12, to receive ACP 2 mg/eye via IVT injections every other month at months 13, 15, 17, 19, 21, and 23 and sham injections at months 12, 14, 16,18, 20, and 22. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Avacincaptad Pegol | Drug | Avacincaptad Pegol Intravitreal Injection |
|
| Measure | Description | Time Frame |
|---|---|---|
| The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by Autofluorescence (FAF) at 3 Time Points: Baseline, Month 6, and Month 12 | GA was associated with age-related macular degeneration (AMD) and caused bilateral, progressive, and irreversible loss of retinal tissue (photoreceptors, retinal pigment epithelium, and choriocapillaris) leading to a permanent loss of visual function and blindness. The least squares mean used to determine mean rate of change in GA growth (slope) was measured by FAF. LS mean & SE were based on square-root transformation. | Baseline to month 12 |
| The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by FAF at 5 Timepoints: Baseline, Month 6, Month 12, Month 18, and Month 24 | GA was associated with AMD and caused bilateral, progressive, and irreversible loss of retinal tissue (photoreceptors, retinal pigment epithelium, and choriocapillaris) leading to a permanent loss of visual function and blindness. The least square mean rate of GA growth (slope) was measured by FAF. LS mean & SE were based on untransformed data. | Baseline to month 24 |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Best Corrected Visual Acuity (BCVA) Using Early Treatment Diabetic Retinopathy Study (ETDRS) Letters at 24 Months | BCVA was assessed using ETDRS visual acuity testing charts. The ETDRS Visual Acuity Score (VAS) is defined as the number of letters read on the ETDRS chart. Minimum and maximum possible scores are 0-100. A higher score represented better visual functioning. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Retina-Vitreous Associates Medical Group | Beverly Hills | California | 90211 | United States | ||
| Retinal Diagnostic Center |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41407269 | Derived | Khanani AM, Danzig CJ, Heier JS, Jaffe GJ, Kaiser PK, Lally DR, Patel SS, Vajzovic L, Weng CY, Patel H, Clark J, Desai D, Luo D, Henry E, Holz FG; GATHER2 Trial Investigators. Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial. Ophthalmology. 2026 Apr;133(4):451-465. doi: 10.1016/j.ophtha.2025.12.011. Epub 2025 Dec 15. | |
| 37696275 |
| Label | URL |
|---|---|
| Link to results and other applicable study documents on the Astellas Clinical Trials website. | View source |
Not provided
Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Not provided
Not provided
Not provided
Not provided
Participants who met all inclusion criteria and none of the exclusion criteria were enrolled in the study.
Participants ≥ 50 years of age diagnosed with geographic atrophy (GA) that was at least partly within 1.5 mm radius from the foveal center were enrolled in the study.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Avacincaptad Pegol | Participants received ACP 2 mg/eye via IVT injections monthly through Month 11 (Year 1). At month 12, participants were re-randomized to receive ACP 2 mg/eye via IVT injections monthly from month12 through month 23 (Year 2). Participants were followed up until month 24. |
| FG001 |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Year 1 (12 Months) |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | May 24, 2021 | Oct 27, 2023 |
Not provided
Not provided
Not provided
Not provided
Not provided
Participant, "Evaluating" Investigator, Reading Center Personnel, and Sponsor Personnel are masked
| Sham | Drug | Sham Administration (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection) |
|
| Baseline and month 24 |
| Change From Baseline in Low Luminance (LL) BCVA Using ETDRS Letters at 24 Months | BCVA was assessed using ETDRS visual acuity testing charts. The ETDRS VAS is defined as the number of letters read on the ETDRS chart. Minimum and maximum possible scores are 0-100. A higher score represented better visual functioning. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. LL BCVA was measured by placing a 2.0 log unit neutral density filter over the best correction for that eye and having the participant read the normally illuminated ETDRS chart. | Baseline and month 24 |
| Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Scores at 6, 12 and 18 Months | The National Eye Institute Visual Function Questionnaire-25 (VFQ-25) measured the influence of visual disability and visual symptoms on general health domains. The VFQ-25 consisted of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. A higher score represented better visual functioning. Each item was then converted to a 0 to 100 scale so that the lowest and highest possible scores were set at 0 and 100 points, respectively. Each subscale score had a range of 0 to 100 inclusive and were calculated from the re-scaled raw data. A composite score was derived based on the average of the 11 vision-related subscales. | Baseline, months 6, 12, and 18 |
| Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Scores at 24 Months | The National Eye Institute Visual Function Questionnaire-25 (VFQ-25) measured the influence of visual disability and visual symptoms on general health domains. The VFQ-25 consisted of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. A higher score represented better visual functioning. Each item was then converted to a 0 to 100 scale so that the lowest and highest possible scores were set at 0 and 100 points, respectively. Each subscale score had a range of 0 to 100 inclusive and were calculated from the re-scaled raw data. A composite score was derived based on the average of the 11 vision-related subscales. | Baseline and month 24 |
| Number of Participants With Categorical One-level Loss in VFQ-25 Subscale | The National Eye Institute VFQ-25 measured the influence of visual disability and visual symptoms on general health domains. The VFQ-25 consisted of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. A higher score represented better visual functioning. Each item was then converted to a 0 to 100 scale so that the lowest and highest possible scores were set at 0 and 100 points, respectively.Categorical one-level loss in each item was defined as decline of one or more levels at Month 24 on the original scale from Baseline (equivalently 20 points for general vision and 25 points for other vision items in a 0 to 100 scale). | Baseline up to month 24 |
| Time to Persistent Vision Loss | Vision loss event was defined as a loss of ≥ 15 letters (equivalent to a loss of 3 lines on the ETDRS chart) in BCVA from Baseline measured at any two or more consecutive visits up to Month 24. These parameters were chosen as a 3-line BCVA loss (equivalent to doubling of visual angle) is widely recognized as a significant deterioration in vision and a minimum of two consecutive visits was representative of persistent disease progression. BCVA was assessed using ETDRS visual acuity testing charts. The ETDRS VAS was defined as the number of letters read on the ETDRS chart. Min and max possible scores are 0-100. A higher score represents better visual functioning. Kaplan-Meier method was used for analysis. Participants with an event were reported and not the median time to event. | Baseline up to month 24 |
| Campbell |
| California |
| 95008 |
| United States |
| Eye Medical Center of Fresno | Fresno | California | 93720 | United States |
| Retina Consultants of Orange County | Fullerton | California | 92835 | United States |
| University of California, San Diego | La Jolla | California | 92093 | United States |
| Jules Stein Eye Institute/David Geffen School of Medicine | Los Angeles | California | 90095 | United States |
| Northern California Retina Vitreous Associates | Mountain View | California | 94040 | United States |
| California Retina Consultants | Oxnard | California | 93036 | United States |
| Southern California Desert Retina Consultants | Palm Desert | California | 92211 | United States |
| Doheny Eye Center, UCLA | Pasadena | California | 91105 | United States |
| Retina Consultants of Southern California | Redlands | California | 92374 | United States |
| Retinal Consultants Medical Group, Inc. | Sacramento | California | 95825 | United States |
| Orange County Retinal Medical Group | Santa Ana | California | 92705 | United States |
| University of Colorado | Aurora | Colorado | 80045 | United States |
| Retina Consultants of Southern Colorado, P.C. | Colorado Springs | Colorado | 80909 | United States |
| Colorado Retina Associates | Lakewood | Colorado | 80228 | United States |
| Connecticut Eye Consultants, P.C. | Danbury | Connecticut | 06810 | United States |
| Retina Group of New England, PC | Waterford | Connecticut | 06385 | United States |
| Florida Eye Clinic | Altamonte Springs | Florida | 32701 | United States |
| Rand Eye Institute | Deerfield Beach | Florida | 33064 | United States |
| Retina Group of Florida | Fort Lauderdale | Florida | 33308 | United States |
| Retina Health Center | Fort Myers | Florida | 33907 | United States |
| National Ophthalmic Research Institute | Fort Myers | Florida | 33912 | United States |
| VitreoRetinal Associates, P.A. | Gainesville | Florida | 32607 | United States |
| Florida Eye Associates | Melbourne | Florida | 32901 | United States |
| University of Miami-Bascom Palmer Eye Institute | Miami | Florida | 33136 | United States |
| Retina Care Specialists | Palm Beach Gardens | Florida | 33410 | United States |
| Retina Specialty Institute | Pensacola | Florida | 32503 | United States |
| Retina Associates of Sarasota | Sarasota | Florida | 34233 | United States |
| Retina Vitreous Associates of Florida | St. Petersburg | Florida | 33711 | United States |
| East Florida Eye Institute | Stuart | Florida | 34994 | United States |
| Southern Vitreoretinal Associates, PL | Tallahassee | Florida | 32308 | United States |
| Center for Retina and Macula Disease | Winter Haven | Florida | 33880 | United States |
| Southeast Retina Center | Augusta | Georgia | 30909 | United States |
| Georgia Retina, P.C. | Marietta | Georgia | 30060 | United States |
| Retina Consultants of Hawaii, Inc | ‘Aiea | Hawaii | 96701 | United States |
| University Retina and Macula Associates, PC | Lemont | Illinois | 60439 | United States |
| Illinois Eye Center | Peoria | Illinois | 61615 | United States |
| Midwest Eye Institute | Indianapolis | Indiana | 46290 | United States |
| Wolfe Eye Clinic | West Des Moines | Iowa | 50266 | United States |
| Retina Associates, LLC | Lenexa | Kansas | 66215 | United States |
| Vitreo Retinal Consultants & Surgeons | Wichita | Kansas | 67214 | United States |
| Ochsner Medical Center | New Orleans | Louisiana | 70121 | United States |
| The Retina Care Center | Baltimore | Maryland | 21209 | United States |
| The Retina Group of Washington | Chevy Chase | Maryland | 20815 | United States |
| Cumberland Valley Retina Consultants | Hagerstown | Maryland | 21740 | United States |
| Ophthalmic Consultants of Boston | Boston | Massachusetts | 02114 | United States |
| Retina Research Institute at New England Retinal Consultants | Springfield | Massachusetts | 01107 | United States |
| UMASS Memorial Eye Center | Worcester | Massachusetts | 01605 | United States |
| Vitreoretinal Associates, PC | Worcester | Massachusetts | 01605 | United States |
| Associated Retinal Consultants, P.C. | Royal Oak | Michigan | 48073 | United States |
| Retina Center | Minneapolis | Minnesota | 55404 | United States |
| St. Louis University | St Louis | Missouri | 63110 | United States |
| Retina Consultants of Nevada | Henderson | Nevada | 89052 | United States |
| Sierra Eye Associates | Reno | Nevada | 89502 | United States |
| Retina Center of New Jersey, LLC | Bloomfield | New Jersey | 07003 | United States |
| Long Island Vitreoretinal Consultant | Great Neck | New York | 11021 | United States |
| Retina Vitreous Surgeons of Central New York, PC | Liverpool | New York | 13088 | United States |
| Vitreous Retina Macula Consultants of New York (VRMNY) | New York | New York | 10022 | United States |
| OCLI | Oceanside | New York | 11572 | United States |
| Retina Associates of Western NY, PC | Rochester | New York | 14620 | United States |
| Ophthalmic Consultants of the Capital Region | Troy | New York | 12180 | United States |
| Western Carolina Retinal Associates | Asheville | North Carolina | 28803 | United States |
| Cincinnati Eye Institute | Cincinnati | Ohio | 45242 | United States |
| Retina and Vitreous Center of Southern Oregon | Ashland | Oregon | 97520 | United States |
| Retina Northwest, PC | Portland | Oregon | 97221 | United States |
| EyeHealth Northwest | Portland | Oregon | 97225 | United States |
| Casey Eye Institute | Portland | Oregon | 97239 | United States |
| Scheie Eye Institute, University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | United States |
| Mid Atlantic Retina | Philadelphia | Pennsylvania | 19107 | United States |
| Associates in Ophthalmology, Ltd | West Mifflin | Pennsylvania | 15122 | United States |
| Retina Research of Beaufort, LLC | Beaufort | South Carolina | 29902 | United States |
| Charleston Neuroscience Institute | Ladson | South Carolina | 29456 | United States |
| Carolina Macula and Retina | Mt. Pleasant | South Carolina | 29464 | United States |
| Palmetto Retina Center | West Columbia | South Carolina | 29169 | United States |
| Black Hills Regional Eye Institute | Rapid City | South Dakota | 57701 | United States |
| Southeastern Retina Associates, PC | Johnson City | Tennessee | 37604 | United States |
| Southeastern Retina Associates, PC | Knoxville | Tennessee | 37922 | United States |
| Retina Research Institute of Texas | Abilene | Texas | 79606 | United States |
| Southwest Retina Specialists | Amarillo | Texas | 79106 | United States |
| Austin Retina Associates | Austin | Texas | 78705 | United States |
| Retina Foundation of the Southwest | Dallas | Texas | 75231 | United States |
| Retina and Vitreous of Texas, PLLC | Houston | Texas | 77025 | United States |
| Valley Retina Institute | McAllen | Texas | 78503 | United States |
| Medical Center Ophthalmology Associates | San Antonio | Texas | 78240 | United States |
| Retina Center of Texas | Southlake | Texas | 76092 | United States |
| Retinal Consultants of Houston | The Woodlands | Texas | 77384 | United States |
| Strategic Clinical Research Group | Willow Park | Texas | 76087 | United States |
| Retinal Associates of Utah | Salt Lake City | Utah | 84107 | United States |
| Rocky Mountain Retina Consultants | Salt Lake City | Utah | 84107 | United States |
| University of Utah, John A. Moran Eye Center | Salt Lake City | Utah | 84132 | United States |
| Wagner Macular & Retina Center | Norfolk | Virginia | 23502 | United States |
| Retina Institute of Virginia | Richmond | Virginia | 23235 | United States |
| Vistar Eye Center | Roanoke | Virginia | 24018 | United States |
| Pacific Northwest Retina | Bellevue | Washington | 98004 | United States |
| Retina Center NW, PLLC | Silverdale | Washington | 98383 | United States |
| Centro Oftalmológico Dr. Charles SA | Buenos Aires | Buenos Aires F.D. | C1116ABA | Argentina |
| Buenos Aires Macula S.A. | Buenos Aires | Buenos Aires F.D. | Cl061AAE | Argentina |
| Centro Médico Grupo Laser Visión | Rosario | Santa Fe Province | CP2000 | Argentina |
| Centro de Diagnóstico y Cirugía Ocular "Oftalmólogos Especialistas" | Rosario | Santa Fe Province | S2000ANJ | Argentina |
| Instituto Oftalmológico de Buenos Aires | Buenos Aires | C1120AAN | Argentina |
| Centro Privado de Ojos Romagosa S.A. | Córdoba | X5000AAJ | Argentina |
| Instituto Oftalmológico de Córdoba | Córdoba | X5000III | Argentina |
| Centro Privado de Oftalmologia - OFTAR Mendoza SRL | Mendoza | M5500GGK | Argentina |
| Centro Medico Micro Diagnostico y Microcirugla Ocular | Rosario | S2000TC | Argentina |
| Sydney Eye Hospital | Sydney | New South Wales | 2000 | Australia |
| Sydney Retina Clinic and Day Surgery | Sydney | New South Wales | 2000 | Australia |
| Royal Victorian Eye & Ear Hospital | East Melbourne | 3002 | Australia |
| Medizinische Universitaet Graz - Augenklinik | Graz | 8036 | Austria |
| Medizinische Universitaet Innsbruck - Universitaetsklinik fuer Augenheilkunde und Optometrie | Innsbruck | 6020 | Austria |
| Medical University of Vienna | Vienna | 1090 | Austria |
| Hanush Hospital | Vienna | 1140 | Austria |
| CHU Brugmann | Brussels | Belgium |
| Centro de Ensino e Pesquisa do Instituto da Visao (CEPIV) | Belo Horizonte | 30330 | Brazil |
| IPEPO - Instituto da visão | São Paulo | 04038-032 | Brazil |
| Hospital Sao Paulo - UNIFESP | Vila Clementino | 04023-062 | Brazil |
| Calgary Retina Consultants | Calgary | Alberta | T2H 0C8 | Canada |
| UBC/VGH Eye Care Center | Vancouver | British Columbia | V5Z3N9 | Canada |
| St.Joseph's Health Care London | London | Ontario | N6A4V2 | Canada |
| Canadian Centre for Advanced Eye Therapeutics Inc. | Mississauga | Ontario | L4W 1W9 | Canada |
| University of Ottawa Eye Institute | Ottawa | Ontario | K1H8L6 | Canada |
| University Health Network | Toronto | Ontario | M5T 2S8 | Canada |
| Retina Centre of Ottawa | Ottawa | K2B 7E9 | Canada |
| Clinica De Oftalmologia Sandiego | Medellín | Antioquia | 050016 | Colombia |
| Fundacion OJlalmologica Nacional - FUNDONAL | Bogotá | 110311 | Colombia |
| Clinical hospital Center Osijek | Osijek | 31000 | Croatia |
| Axon Clinical s.r.o. | Prague | Smichov | 150 00 | Czechia |
| Dr Kai Noor Silmakabinet | Tallinn | 11412 | Estonia |
| Tartu University Hospital | Tartu | 50406 | Estonia |
| CHU de Bordeaux - Hopital Pellegrin | Bordeaux | 33000 | France |
| Hopital Intercommunal | Créteil | 94010 | France |
| CHU Bocage | Dijon | 21079 | France |
| Centre Pole Vision Val d'Ouest | Écully | 69130 | France |
| Centre d'ophtalmologie Rabelais | Lyon | 69002 | France |
| Hopital de la Croix Rousse | Lyon | 69004 | France |
| Centre Paradis Monticelli | Marseille | 13008 | France |
| CHU de Nantes | Nantes | 44043 | France |
| Centre d'exploration ophtalmologique de l'Odeon | Paris | 75006 | France |
| Hôpital Lariboisière | Paris | 75010 | France |
| Centre Ophtalmologique d'Imagerie et de Laser | Paris | 75015 | France |
| Fondation Alolphe de Rotschild | Paris | 75019 | France |
| Centre St Exupery | Saint-Cyr-sur-Loire | 37540 | France |
| RWTH Aachen University | Aachen | 52074 | Germany |
| University of Bonn | Bonn | Germany |
| Augenklinik University Hospital Cologne | Cologne | 50937 | Germany |
| University of Göttingen | Göttingen | 37075 | Germany |
| Universitätsklinikum Hamburg Eppendorf Klinik und Poliklinik für Augenheilkunde Studienzentrum | Hamburg | 20251 | Germany |
| University Eye Hospital, MHH | Hanover | 30625 | Germany |
| University clinic Leipzig AÖR | Leipzig | 04103 | Germany |
| Universitätsklinikum Schleswig-Holstein | Lübeck | 23538 | Germany |
| Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Mainz | 55131 | Germany |
| Ludwig-Maximilians-University Munich | Munich | 80336 | Germany |
| Clinic Rechts der Isar | Munich | 81675 | Germany |
| Augenzentrum am St. Franziskus-Hospital | Münster | 48145 | Germany |
| Universitätsklinikum Münster | Münster | 48149 | Germany |
| Universitäts-Augenklinik | Tübingen | 72076 | Germany |
| Hungarian Military Hospital Center | Budapest | 1068 | Hungary |
| Bajcsy Zsilinszky Kórház - Szemészet | Budapest | 1106 | Hungary |
| Budapest Retina Associates | Budapest | 1133 | Hungary |
| Semmelweis University, Dept of Ophthalmology | Budapest | H-1085 | Hungary |
| Debrecen University Clinical Center, Dept of Ophthalmology | Debrecen | H-4032 | Hungary |
| Szabolcs-Szatmar-Bereg County Hospital and University Teaching Hospital | Nyíregyháza | 4400 | Hungary |
| Ganglion Medical Center | Pécs | H-7621 | Hungary |
| Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont | Szeged | H-6720 | Hungary |
| Barzilai Medical Center | Ashkelon | 7830604 | Israel |
| Shamir Medical Center | Be’er Ya‘aqov | 70300 | Israel |
| Rambam Medical Centre | Haifa | 3109601 | Israel |
| Carmel Medical Center | Haifa | 3436212 | Israel |
| Edith Wolfson Medical Center | Holon | 5822012 | Israel |
| Hadassah University Hospital | Jerusalem | 91120 | Israel |
| Department of Ophthalmology, Rabin Medical Center | Petah Tikva | 49100 | Israel |
| Kaplan Medical Center | Rehovot | 76100 | Israel |
| Sourasky Medical Center | Tel Aviv | 6423906 | Israel |
| Ospedali Riuniti di Ancona | Ancona | 60126 | Italy |
| A.O.U. Policlinico Sant'Orsola-Malpighi | Bologna | 40138 | Italy |
| Ospedale Clinicizzato Universita di Chieti "Ss Annunziata" | Chieti | 66100 | Italy |
| Nuovo Arcispedale Sant' Anna (A.O.U. di Ferrara) | Ferrara | 44124 | Italy |
| Azienda Ospedaliera Universitaria Careggi | Florence | 50134 | Italy |
| Ospedale Maggiore Policlinico Milano | Milan | 20122 | Italy |
| IRCCS Ospedale San Raffaele | Milan | 20132 | Italy |
| Ospedale Luigi Sacco | Milan | 20157 | Italy |
| AOU Universita degli Studi della Campania Luigi Vanvitelli UOC Oculistica | Naples | 80131 | Italy |
| Azienda Ospedaliera di Padova Unità Operativa Complessa di Clinica Oculistica | Padova | 35128 | Italy |
| University of Pisa | Pisa | 56126 | Italy |
| Fondazione PTV | Roma | 00133 | Italy |
| Fondazione GB Bietti IRCCS | Roma | 00198 | Italy |
| Azienda Sanitaria Universitaria Integrata | Udine | 33100 | Italy |
| Pauls Stradinis Clinical University Hospital | Riga | LV-1002 | Latvia |
| Klinika Okulistyczna OFT ALMIKA Sp. z o. o. | Bydgoszcz | 85-631 | Poland |
| Medical Center Julianów | Lodz | 91-485 | Poland |
| Caminomed | Tarnowskie Góry | 42-600 | Poland |
| Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego | Wroclaw | 50-556 | Poland |
| Clinica de Oftalmologia Barraquer | Barcelona | 08021 | Spain |
| Institut Catala de Retina | Barcelona | 08022 | Spain |
| Institut de la Macula | Barcelona | 08022 | Spain |
| VOR - Hospital General de Catalunya | Barcelona | 08195 | Spain |
| Instituto Clinico Quirurgico de Oftalmologia | Bilbao | 48010 | Spain |
| Hospital La Arruzafa | Córdoba | CP 14012 | Spain |
| H.U. Puerta de Hierro-Majadahonda | Majadahonda | 28222 | Spain |
| Clinica Universidad de Navarra | Pamplona | 31008 | Spain |
| Instituto Oftalmologico Gomez-Ulla | Santiago de Compostela | 15706 | Spain |
| IMED Servicio Oftalmología | Valencia | 46100 | Spain |
| Rio Hortega University Hospital | Valladolid | 47012 | Spain |
| Hospital Clínico Universitario "Lozano Blesa" | Zaragoza | 50009 | Spain |
| Hull University Teaching Hospitals NHS Trust | Hull | HU3 2JZ | United Kingdom |
| Derived |
| Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, Hsu J, Wykoff CC, Heier JS, Lally DR, Mones J, Nielsen JS, Sheth VS, Kaiser PK, Clark J, Zhu L, Patel H, Tang J, Desai D, Jaffe GJ; GATHER2 trial investigators. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet. 2023 Oct 21;402(10411):1449-1458. doi: 10.1016/S0140-6736(23)01583-0. Epub 2023 Sep 8. |
| 37314061 | Derived | Tzoumas N, Riding G, Williams MA, Steel DH. Complement inhibitors for age-related macular degeneration. Cochrane Database Syst Rev. 2023 Jun 14;6(6):CD009300. doi: 10.1002/14651858.CD009300.pub3. |
| Link to plain language summary of the study on the Trial Results Summaries website. | View source |
| Avacincaptad Pegol and Sham |
Participants received ACP 2 mg/eye via IVT injections monthly through Month 11 (Year 1). At month 12, participants were re-randomized to receive ACP 2 mg/eye via IVT every other month (EOM) at months 13, 15, 17, 19, 21, and 23 and sham injections at months 12, 14, 16,18, 20, and 22 (Year 2). Participants were followed up until month 24. |
| FG002 | Sham | Participants received sham injections; through Month 11 (Year 1). At month 12, participants continued to receive monthly sham injection from month 12 through month 23 (Year 2). Participants were followed up until month 24. |
| Treated |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
| Year 2 (12 Months) |
|
|
Intent-to-treat (ITT) analysis set consisted of all randomized participants who received at least 1 dose of study drug.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Avacincaptad Pegol | Participants received ACP 2 mg/eye via IVT injections monthly through Month 11 (Year 1). At month 12, participants were re-randomized to receive ACP 2 mg/eye via IVT injections monthly or ACP 2 mg/eye via IVT injections EOM at months 13, 15, 17, 19, 21, and 23 and sham injections at months 12, 14, 16,18, 20, and 22 (Year 2). Participants were followed up until month 24. |
| BG001 | Sham | Participants received sham injections; through Month 11 (Year 1). At month 12, participants continued to receive monthly sham injection from month 12 through month 23 (Year 2). Participants were followed up until month 24. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by Autofluorescence (FAF) at 3 Time Points: Baseline, Month 6, and Month 12 | GA was associated with age-related macular degeneration (AMD) and caused bilateral, progressive, and irreversible loss of retinal tissue (photoreceptors, retinal pigment epithelium, and choriocapillaris) leading to a permanent loss of visual function and blindness. The least squares mean used to determine mean rate of change in GA growth (slope) was measured by FAF. LS mean & SE were based on square-root transformation. | ITT analysis set | Posted | Least Squares Mean | Standard Error | millimeters (mm)/year | Baseline to month 12 |
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by FAF at 5 Timepoints: Baseline, Month 6, Month 12, Month 18, and Month 24 | GA was associated with AMD and caused bilateral, progressive, and irreversible loss of retinal tissue (photoreceptors, retinal pigment epithelium, and choriocapillaris) leading to a permanent loss of visual function and blindness. The least square mean rate of GA growth (slope) was measured by FAF. LS mean & SE were based on untransformed data. | Re-rand analysis set-The subset of the ITT analysis set who were re-randomized at Month 12 and who were on sham and completed the Month 12 visit. | Posted | Least Squares Mean | Standard Error | mm^2/year | Baseline to month 24 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Best Corrected Visual Acuity (BCVA) Using Early Treatment Diabetic Retinopathy Study (ETDRS) Letters at 24 Months | BCVA was assessed using ETDRS visual acuity testing charts. The ETDRS Visual Acuity Score (VAS) is defined as the number of letters read on the ETDRS chart. Minimum and maximum possible scores are 0-100. A higher score represented better visual functioning. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. | ITT analysis set | Posted | Least Squares Mean | Standard Error | score on a scale | Baseline and month 24 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Low Luminance (LL) BCVA Using ETDRS Letters at 24 Months | BCVA was assessed using ETDRS visual acuity testing charts. The ETDRS VAS is defined as the number of letters read on the ETDRS chart. Minimum and maximum possible scores are 0-100. A higher score represented better visual functioning. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. LL BCVA was measured by placing a 2.0 log unit neutral density filter over the best correction for that eye and having the participant read the normally illuminated ETDRS chart. | ITT analysis set | Posted | Least Squares Mean | Standard Error | score on a scale | Baseline and month 24 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Scores at 6, 12 and 18 Months | The National Eye Institute Visual Function Questionnaire-25 (VFQ-25) measured the influence of visual disability and visual symptoms on general health domains. The VFQ-25 consisted of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. A higher score represented better visual functioning. Each item was then converted to a 0 to 100 scale so that the lowest and highest possible scores were set at 0 and 100 points, respectively. Each subscale score had a range of 0 to 100 inclusive and were calculated from the re-scaled raw data. A composite score was derived based on the average of the 11 vision-related subscales. | ITT analysis set with available data was analyzed | Posted | Mean | Standard Deviation | score on a scale | Baseline, months 6, 12, and 18 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Scores at 24 Months | The National Eye Institute Visual Function Questionnaire-25 (VFQ-25) measured the influence of visual disability and visual symptoms on general health domains. The VFQ-25 consisted of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. A higher score represented better visual functioning. Each item was then converted to a 0 to 100 scale so that the lowest and highest possible scores were set at 0 and 100 points, respectively. Each subscale score had a range of 0 to 100 inclusive and were calculated from the re-scaled raw data. A composite score was derived based on the average of the 11 vision-related subscales. | ITT analysis | Posted | Least Squares Mean | Standard Error | score on a scale | Baseline and month 24 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Categorical One-level Loss in VFQ-25 Subscale | The National Eye Institute VFQ-25 measured the influence of visual disability and visual symptoms on general health domains. The VFQ-25 consisted of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. A higher score represented better visual functioning. Each item was then converted to a 0 to 100 scale so that the lowest and highest possible scores were set at 0 and 100 points, respectively.Categorical one-level loss in each item was defined as decline of one or more levels at Month 24 on the original scale from Baseline (equivalently 20 points for general vision and 25 points for other vision items in a 0 to 100 scale). | ITT analysis set with available data was analyzed | Posted | Number | participants | Baseline up to month 24 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Time to Persistent Vision Loss | Vision loss event was defined as a loss of ≥ 15 letters (equivalent to a loss of 3 lines on the ETDRS chart) in BCVA from Baseline measured at any two or more consecutive visits up to Month 24. These parameters were chosen as a 3-line BCVA loss (equivalent to doubling of visual angle) is widely recognized as a significant deterioration in vision and a minimum of two consecutive visits was representative of persistent disease progression. BCVA was assessed using ETDRS visual acuity testing charts. The ETDRS VAS was defined as the number of letters read on the ETDRS chart. Min and max possible scores are 0-100. A higher score represents better visual functioning. Kaplan-Meier method was used for analysis. Participants with an event were reported and not the median time to event. | ITT analysis set | Posted | Median | Full Range | months | Baseline up to month 24 |
|
All-cause mortality (ACM): From randomization up to 24 months Serious Adverse events (SAEs) and non-SAEs: From first dose up to 24 months
Participants in "ACP only" & "ACP and Sham" groups were treated with ACP for up to 2 years, hence safety of ACP is more accurately represented by the randomized ACP group.
ACM: All randomized participants. Serious & non-SAEs: Those who received at least 1 dose of treatment. Those who received injection of ACP were analyzed in ACP group according to actual injections. One participant randomized to sham didn't receive treatment & was included in denominator for ACM only and not for other outcomes.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Avacincaptad Pegol Only (up to 12 Months) | Participants received ACP 2 mg/eye via IVT injections monthly through Month 11 (Year 1). | 4 | 225 | 31 | 225 | 100 | 225 |
| EG001 | Avacincaptad Pegol Only (12 to 24 Months) | Participants were re-randomized at month 12 to receive ACP 2 mg/eye via IVT injections monthly from month 12 through month 23 (Year 2). Participants were followed up until month 24. | 1 | 96 | 18 | 96 | 51 | 96 |
| EG002 | Avacincaptad Pegol and Sham Only (12 to 24 Months) | Participants were re-randomized at month 12, to receive ACP 2 mg/eye via IVT injections every other month at months 13, 15, 17, 19, 21, and 23 and sham injections at months 12, 14, 16,18, 20, and 22 (Year 2). Participants were followed up until month 24. | 4 | 93 | 16 | 93 | 41 | 93 |
| EG003 | Sham Only (up to 12 Months) | Participants received sham injections through Month 11 (Year 1). | 1 | 222 | 36 | 222 | 83 | 222 |
| EG004 | Sham Only (12 to 24 Months) | Participants continued to receive monthly sham injection from month 12 through month 23 (Year 2). Participants were followed up until month 24. | 7 | 203 | 25 | 203 | 77 | 203 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Microcytic anaemia | Blood and lymphatic system disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Normocytic anaemia | Blood and lymphatic system disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Acute myocardial infarction | Cardiac disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Angina pectoris | Cardiac disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Atrial fibrillation | Cardiac disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Atrial flutter | Cardiac disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Atrial tachycardia | Cardiac disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Atrioventricular block second degree | Cardiac disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Cardiac failure | Cardiac disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Cardiac failure chronic | Cardiac disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Cardiac failure congestive | Cardiac disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Cardio-respiratory arrest | Cardiac disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Coronary artery disease | Cardiac disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Coronary artery insufficiency | Cardiac disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Intracardiac thrombus | Cardiac disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Mitral valve incompetence | Cardiac disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Myocardial infarction | Cardiac disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Myocardial ischaemia | Cardiac disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Sinus arrest | Cardiac disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Ventricular extrasystoles | Cardiac disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Mobile caecum syndrome | Congenital, familial and genetic disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Vertigo | Ear and labyrinth disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Choroidal neovascularisation | Eye disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Retinal haemorrhage | Eye disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Visual acuity reduced | Eye disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Visual acuity reduced transiently | Eye disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Barrett's oesophagus | Gastrointestinal disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Enterovesical fistula | Gastrointestinal disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Gastric haemorrhage | Gastrointestinal disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Haemorrhoidal haemorrhage | Gastrointestinal disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Inguinal hernia | Gastrointestinal disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Large intestine polyp | Gastrointestinal disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Oesophageal spasm | Gastrointestinal disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Pancreatitis chronic | Gastrointestinal disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Rectal haemorrhage | Gastrointestinal disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Small intestinal obstruction | Gastrointestinal disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Upper gastrointestinal haemorrhage | Gastrointestinal disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Chest pain | General disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Biliary obstruction | Hepatobiliary disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Cholecystitis acute | Hepatobiliary disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Hepatic cirrhosis | Hepatobiliary disorders | MedDRA v24.1 | Systematic Assessment |
| |
| COVID-19 | Infections and infestations | MedDRA v24.1 | Systematic Assessment |
| |
| COVID-19 pneumonia | Infections and infestations | MedDRA v24.1 | Systematic Assessment |
| |
| Clostridium difficile colitis | Infections and infestations | MedDRA v24.1 | Systematic Assessment |
| |
| Clostridium difficile infection | Infections and infestations | MedDRA v24.1 | Systematic Assessment |
| |
| Cystitis bacterial | Infections and infestations | MedDRA v24.1 | Systematic Assessment |
| |
| Diverticulitis | Infections and infestations | MedDRA v24.1 | Systematic Assessment |
| |
| Diverticulitis intestinal perforated | Infections and infestations | MedDRA v24.1 | Systematic Assessment |
| |
| Endophthalmitis | Infections and infestations | MedDRA v24.1 | Systematic Assessment |
| |
| Herpes zoster | Infections and infestations | MedDRA v24.1 | Systematic Assessment |
| |
| Listeria sepsis | Infections and infestations | MedDRA v24.1 | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA v24.1 | Systematic Assessment |
| |
| Pneumonia bacterial | Infections and infestations | MedDRA v24.1 | Systematic Assessment |
| |
| Postoperative abscess | Infections and infestations | MedDRA v24.1 | Systematic Assessment |
| |
| Sepsis | Infections and infestations | MedDRA v24.1 | Systematic Assessment |
| |
| Urosepsis | Infections and infestations | MedDRA v24.1 | Systematic Assessment |
| |
| Wound infection | Infections and infestations | MedDRA v24.1 | Systematic Assessment |
| |
| Ankle fracture | Injury, poisoning and procedural complications | MedDRA v24.1 | Systematic Assessment |
| |
| Exposure to toxic agent | Injury, poisoning and procedural complications | MedDRA v24.1 | Systematic Assessment |
| |
| Facial bones fracture | Injury, poisoning and procedural complications | MedDRA v24.1 | Systematic Assessment |
| |
| Fall | Injury, poisoning and procedural complications | MedDRA v24.1 | Systematic Assessment |
| |
| Femur fracture | Injury, poisoning and procedural complications | MedDRA v24.1 | Systematic Assessment |
| |
| Humerus fracture | Injury, poisoning and procedural complications | MedDRA v24.1 | Systematic Assessment |
| |
| Joint injury | Injury, poisoning and procedural complications | MedDRA v24.1 | Systematic Assessment |
| |
| Lumbar vertebral fracture | Injury, poisoning and procedural complications | MedDRA v24.1 | Systematic Assessment |
| |
| Multiple fractures | Injury, poisoning and procedural complications | MedDRA v24.1 | Systematic Assessment |
| |
| Procedural intestinal perforation | Injury, poisoning and procedural complications | MedDRA v24.1 | Systematic Assessment |
| |
| Procedural pain | Injury, poisoning and procedural complications | MedDRA v24.1 | Systematic Assessment |
| |
| Radius fracture | Injury, poisoning and procedural complications | MedDRA v24.1 | Systematic Assessment |
| |
| Rib fracture | Injury, poisoning and procedural complications | MedDRA v24.1 | Systematic Assessment |
| |
| Spinal compression fracture | Injury, poisoning and procedural complications | MedDRA v24.1 | Systematic Assessment |
| |
| Spinal fracture | Injury, poisoning and procedural complications | MedDRA v24.1 | Systematic Assessment |
| |
| Subdural haematoma | Injury, poisoning and procedural complications | MedDRA v24.1 | Systematic Assessment |
| |
| Tibia fracture | Injury, poisoning and procedural complications | MedDRA v24.1 | Systematic Assessment |
| |
| Traumatic intracranial haemorrhage | Injury, poisoning and procedural complications | MedDRA v24.1 | Systematic Assessment |
| |
| Upper limb fracture | Injury, poisoning and procedural complications | MedDRA v24.1 | Systematic Assessment |
| |
| Wrist fracture | Injury, poisoning and procedural complications | MedDRA v24.1 | Systematic Assessment |
| |
| Type 2 diabetes mellitus | Metabolism and nutrition disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Intervertebral disc protrusion | Musculoskeletal and connective tissue disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Lumbar spinal stenosis | Musculoskeletal and connective tissue disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Osteoarthritis | Musculoskeletal and connective tissue disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Tenosynovitis | Musculoskeletal and connective tissue disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Acute leukaemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v24.1 | Systematic Assessment |
| |
| Basal cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v24.1 | Systematic Assessment |
| |
| Breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v24.1 | Systematic Assessment |
| |
| Colon cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v24.1 | Systematic Assessment |
| |
| Meningioma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v24.1 | Systematic Assessment |
| |
| Non-small cell lung cancer stage IIIA | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v24.1 | Systematic Assessment |
| |
| Sinonasal papilloma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v24.1 | Systematic Assessment |
| |
| Squamous cell carcinoma of lung | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v24.1 | Systematic Assessment |
| |
| Cerebral haemorrhage | Nervous system disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Cerebral infarction | Nervous system disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Cerebrovascular accident | Nervous system disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Intracranial aneurysm | Nervous system disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Metabolic encephalopathy | Nervous system disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Neuromyelitis optica spectrum disorder | Nervous system disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Transient ischaemic attack | Nervous system disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Device dislocation | Product Issues | MedDRA v24.1 | Systematic Assessment |
| |
| Device lead damage | Product Issues | MedDRA v24.1 | Systematic Assessment |
| |
| Prostatitis | Reproductive system and breast disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Acute respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Dyspnoea exertional | Respiratory, thoracic and mediastinal disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Emphysema | Respiratory, thoracic and mediastinal disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Pleural effusion | Respiratory, thoracic and mediastinal disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Pneumothorax | Respiratory, thoracic and mediastinal disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Aortic aneurysm | Vascular disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Aortic stenosis | Vascular disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Circulatory collapse | Vascular disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Hypertension | Vascular disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Hypertensive emergency | Vascular disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Neurogenic shock | Vascular disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Peripheral arterial occlusive disease | Vascular disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Peripheral artery occlusion | Vascular disorders | MedDRA v24.1 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Cataract | Eye disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Choroidal neovascularisation | Eye disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Conjunctival haemorrhage | Eye disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Conjunctival hyperaemia | Eye disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Punctate keratitis | Eye disorders | MedDRA v24.1 | Systematic Assessment |
| |
| Retinal haemorrhage | Eye disorders | MedDRA v24.1 | Systematic Assessment |
| |
| COVID-19 | Infections and infestations | MedDRA v24.1 | Systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA v24.1 | Systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | MedDRA v24.1 | Systematic Assessment |
| |
| Fall | Injury, poisoning and procedural complications | MedDRA v24.1 | Systematic Assessment |
| |
| Intraocular pressure increased | Investigations | MedDRA v24.1 | Systematic Assessment |
|
No individual site or investigator may publish or present any results from the trial until a joint, multi-center publication of the trial results is made by Sponsor in conjunction with various participating investigators and appropriate sites contributing data and comments. Subsequently, individual investigators may request to publish or present results from the trial; however approval will be at the sole discretion of the Sponsor.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Clinical Transparency | Astellas Pharma Global Development, Inc | 800-888-7704 | astellas.resultsdisclosure@astellas.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Apr 7, 2022 | Jul 26, 2024 | SAP_002.pdf |
Not provided
| ID | Term |
|---|---|
| D057092 | Geographic Atrophy |
| D008268 | Macular Degeneration |
| ID | Term |
|---|---|
| D012162 | Retinal Degeneration |
| D012164 | Retinal Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C005703 | salicylhydroxamic acid |
Not provided
Not provided
Not provided
| Withdrawal by Subject |
|
| Adverse Event |
|
| Male |
|
| Not Hispanic or Latino |
|
| Unknown or Not Reported |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| OG002 | Sham | Participants received sham injections; through Month 11 (Year 1). At month 12, participants continued to receive monthly sham injection from month 12 through month 23 (Year 2). Participants were followed up until month 24. |
|
|
|
| Participants |
|
|
|
| Units | Counts |
|---|
| Participants |
|
|
|
|
|
|
|
|
|
|
|
|
|